Literature DB >> 28708712

Extended Second Window of Protection of Sevoflurane-induced Preconditioning.

Friederike Behmenburg1, Yvonne Boekholt, Patrick van Caster, Marianne Dorsch, André Heinen, Markus W Hollmann, Ragnar Huhn.   

Abstract

Late preconditioning (LPC) can be induced by volatile anesthetics and initiates cardioprotection against ischemia/reperfusion injury for 3-4 days. We investigated the possibility to extend the time window of sevoflurane-induced LPC by repeated sevoflurane administration. An in vivo rat model of regional myocardial ischemia/reperfusion injury was used. Myocardial infarct size was determined by triphenyltetrazolium chloride staining at the end of the experiment. In the first series of experiments, male Wistar rats were randomized to 5 groups (each n = 8). Control animals were not treated further. Animals in the preconditioning groups inhaled sevoflurane for 60 minutes (1 MAC) 24, 48, 72, and 96 hours, respectively, before myocardial ischemia. Based on the findings of the first experimental series, another 6 groups of animals were investigated. Again, control animals were left untreated; all other animals received a second sevoflurane stimulus 72 hours after the first sevoflurane treatment, and myocardial ischemia was induced 24, 48, 72, and 96 hours, respectively, after the second sevoflurane treatment to investigate, whether the cardioprotective effect could be extended. Sevoflurane reduced infarct size after 24, 48, and 72 hours (each P < 0.05 vs. control) but not after 96 hours. The repeated administration of sevoflurane 72 hours after the first stimulus extended the time window of protection for additional 72 hours (each P < 0.05 vs. control). There was no myocardial protection 4 days after the second preconditioning stimulus. The time window of sevoflurane-induced LPC can be extended by an additional sevoflurane stimulus up to 72 hours after the initial sevoflurane exposure.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28708712     DOI: 10.1097/FJC.0000000000000517

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  4 in total

Review 1.  Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection.

Authors:  Hans Erik Bøtker; Derek Hausenloy; Ioanna Andreadou; Salvatore Antonucci; Kerstin Boengler; Sean M Davidson; Soni Deshwal; Yvan Devaux; Fabio Di Lisa; Moises Di Sante; Panagiotis Efentakis; Saveria Femminò; David García-Dorado; Zoltán Giricz; Borja Ibanez; Efstathios Iliodromitis; Nina Kaludercic; Petra Kleinbongard; Markus Neuhäuser; Michel Ovize; Pasquale Pagliaro; Michael Rahbek-Schmidt; Marisol Ruiz-Meana; Klaus-Dieter Schlüter; Rainer Schulz; Andreas Skyschally; Catherine Wilder; Derek M Yellon; Peter Ferdinandy; Gerd Heusch
Journal:  Basic Res Cardiol       Date:  2018-08-17       Impact factor: 17.165

2.  The Protective Effect of Sevoflurane Conditionings Against Myocardial Ischemia/Reperfusion Injury: A Systematic Review and Meta-Analysis of Preclinical Trials in in-vivo Models.

Authors:  Bin Hu; Tian Tian; Pei-Pei Hao; Wei-Chao Liu; Ying-Gui Chen; Tian-Yu Jiang; Fu-Shan Xue
Journal:  Front Cardiovasc Med       Date:  2022-04-28

3.  Sevoflurane protects cardiomyocytes against hypoxia/reperfusion injury via LINC01133/miR-30a-5p axis.

Authors:  Zhenyi Yu; Qiusheng Ren; Shenghui Yu; Xiang Gao
Journal:  Biosci Rep       Date:  2020-12-23       Impact factor: 3.840

Review 4.  The Role of Heme Oxygenase-1 in Remote Ischemic and Anesthetic Organ Conditioning.

Authors:  Inge Bauer; Annika Raupach
Journal:  Antioxidants (Basel)       Date:  2019-09-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.